RATIONAL PHARMACOTHERAPY IN THE TREATMENT OF ISCHEMIC HEART DISEASE

Abstract

This scientific article provides an in-depth analysis of the theoretical and practical aspects of rational pharmacotherapy in the treatment of ischemic heart disease (IHD). Ischemic heart diseases mainly include angina pectoris, myocardial infarction, post-infarction cardiosclerosis, chronic heart failure, acute heart failure, cardiac arrhythmias, and coronary insufficiency. The most common forms are angina pectoris and myocardial infarction. Chronic heart failure (CHF) is considered a major complication of the disease.The study examines the clinical efficacy, safety, and principles of using antianginal, antithrombotic, diuretic drugs, cardiac glycosides, ACE inhibitors, lipid-lowering agents, and medications affecting the neurohormonal system. In addition, issues such as individualized treatment approaches, limitation of polypharmacy, and pharmacoeconomic efficiency are discussed. The results obtained demonstrate that rational pharmacotherapy plays a crucial role in improving the prognosis of patients with ischemic heart disease.